Eli Lilly Beats Teva Appeal on Generic Cancer Drug
Eli Lilly blocks Teva from selling a generic equivalent of its lung cancer drug Alimta (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - January 13, 2017 Category: Pharmaceuticals Source Type: news
Sugarbaker Touts New Clinical Study for Mesothelioma Patients
This study expands on what we already know about surgery and chemotherapy for mesothelioma, and combines them in a new way…with the goal of reducing recurrence rates and improving survival and quality of life,” Groth said in a press release from the Baylor Medical Center. “The heated chemotherapy fluid is effective at killing cancer and making the chemotherapy work better.”
Baylor also has other ongoing mesothelioma clinical trials:
A phase II study of anetumab ravtansine for patients with unresectable pleural mesothelioma and high expression of mesothelin, a vulnerable, tumor-surface protein linked to cancer prog...
Source: Asbestos and Mesothelioma News - December 22, 2016 Category: Environmental Health Authors: Walter Pacheco Tags: baylor college of medicine chemotherapy for mesothelioma dr. david sugarbaker mesothelioma chemotherapy drugs mesothelioma clinical trial mesothelioma treatment center at baylor Source Type: news
Mesothelioma Trial for Nintedanib Shows Positive Results
Researchers have reported more promising results from an international, multicenter phase II clinical trial of the drug nintedanib, moving it another step closer to standard-of-care treatment for pleural mesothelioma.
Nintedanib is a small-molecule enzyme inhibitor being studied as a way to increase the effectiveness of chemotherapy on mesothelioma and certain types of lung cancer.
Researchers presented the results earlier this month at the World Conference on Lung Cancer in Vienna, Austria.
The randomized clinical trial treated mesothelioma patients with a placebo and chemotherapy (pemetrexed/cisplatin) or nintedanib and ...
Source: Asbestos and Mesothelioma News - December 22, 2016 Category: Environmental Health Authors: Walter Pacheco Tags: chemotherapy clinical trial chemotherapy for mesothelioma extending mesothelioma survival mesothelioma treatment nintedanib Source Type: news
Study Shows Impact of Chemotherapy on Mesothelioma
A U.S.-based study confirms what oncology experts have suggested for years — chemotherapy treatment prolongs life expectancy for malignant mesothelioma patients.
Wayne State University School of Medicine researchers linked data from the National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) database with Medicare claims data. The study took into account patient characteristics such as age, gender and amount of asbestos exposure.
Not only did the findings show mesothelioma patients who have chemotherapy live longer, but it also proved multimodal therapy increases survival even more. The study is ...
Source: Asbestos and Mesothelioma News - December 19, 2016 Category: Environmental Health Authors: Walter Pacheco Tags: chemotherapy clinical trial chemotherapy for mesothelioma doctor shirish gadgeel first line treatment for mesothelioma Human Investigation Committee at Wayne State mesothelioma diagnosis peritoneal mesothelioma wayne state university Source Type: news
Predictors of Chemotherapy Efficacy in NSCLC Predictors of Chemotherapy Efficacy in NSCLC
Can biomarkers predict the efficacy of conventional chemotherapy, such as gemcitabine and pemetrexed, for treatment of NSCLC?Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 7, 2016 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Adding Pemetrexed to Gefitinib Improves PFS in EGFR-Mutated NSCLC
The combination of pemetrexed and gefitinib offered improved progression-free survival in East Asian patients with advanced nonsquamous NSCLC and activating EGFR mutations. (Source: CancerNetwork)
Source: CancerNetwork - August 8, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Lung Cancer News Source Type: news
New Mesothelioma Treatment Guidelines May Extend Survival
The National Comprehensive Cancer Network (NCCN) has changed its first-line treatment recommendation for unresectable pleural mesothelioma, believing it will extend patient survival significantly.
The NCCN advisory panel recently added the monoclonal antibody bevacizumab to the long-standing chemotherapy combination of pemetrexed and cisplatin.
Bevacizumab, also known by brand name Avastin, inhibits the formation of new blood vessels in tumors, effectively slowing the growth of cancer cells. It has successfully treated some types of lung and colorectal cancers.
The NCCN recommendation is expected to be a precursor to the U...
Source: Asbestos and Mesothelioma News - July 26, 2016 Category: Environmental Health Authors: Walter Pacheco Tags: cancer chemotherapy chemotherapy drugs chemotherapy drugs for mesothelioma chemotherapy for mesothelioma mesothelioma treatment moffitt cancer center new chemotherapy drug Source Type: news
IMPRINT Mesothelioma Treatment Boosts Radiation Therapy
Doctors confirmed a novel radiation procedure can be combined safely and effectively with aggressive lung-sparing surgery to improve survival time and quality of life for patients with mesothelioma.
After a decade of refinement, a small number of mesothelioma specialty centers now are using intensity-modulated pleural radiation therapy (IMPRINT) as part of the recent advancements in multidisciplinary treatments.
“We’re hoping that all centers with experience in treating mesothelioma will now look at this as another technique to put in their arsenal,” radiation oncologist Dr. Kenneth Rosenzweig of the Mount Si...
Source: Asbestos and Mesothelioma News - July 15, 2016 Category: Environmental Health Authors: Walter Pacheco Tags: cancer treatments IMPRINT for mesothelioma lung cancer treatments mesothelioma treatment pleural mesothelioma radiation for mesothelioma radiation therapy Source Type: news
IMPRINT Mesothelioma Treatment Boosts Radiation Therapy
Doctors confirmed a novel radiation procedure can be combined safely and effectively with aggressive lung-sparing surgery to improve survival time and quality of life for patients with mesothelioma.
After a decade of refinement, a small number of mesothelioma specialty centers now are using intensity-modulated pleural radiation therapy (IMPRINT) as part of the recent advancements in multidisciplinary treatments.
“We’re hoping that all centers with experience in treating mesothelioma will now look at this as another technique to put in their arsenal,” radiation oncologist Dr. Kenneth Rosenzweig of the Mount Si...
Source: Asbestos and Mesothelioma News - July 15, 2016 Category: Environmental Health Authors: Walter Pacheco Tags: cancer treatments IMPRINT for mesothelioma lung cancer treatments mesothelioma treatment pleural mesothelioma radiation for mesothelioma radiation therapy Source Type: news
ONCOS-102 Mesothelioma Clinical Trial Promises Hope
Scandinavian-based Targovax launched the latest immunotherapy clinical trial for pleural mesothelioma, hoping it delivers a better way to treat patients with asbestos-related diseases.
The randomized phase Ib/II trial evaluates the performance of ONCOS-102, an engineered human adenovirus designed to induce systemic, anti-tumor responses.
Researchers are administering the immunotherapy drug as first-line therapy in combination with chemotherapy using pemetrexed and cisplatin.
“Based on what we’ve seen in our first study of patients with various solid tumor types, which is good tolerance and response in a couple of mesot...
Source: Asbestos and Mesothelioma News - July 12, 2016 Category: Environmental Health Authors: Walter Pacheco Tags: immunotherapy clinical trial immunotherapy for cancer mesothelioma mesothelioma clinical trials mesothelioma immunotherapy ONCOS 102 Source Type: news
Targovax doses first patient in Phase Ib/II trial of ONCOS-102 to treat MPM
Norwegian-based immuno-oncology company Targovax has dosed the first patient in the Phase Ib/II combination trial of a combination pemetrexed and cisplatin with ONCOS-102 to treat malignant pleural mesothelioma (MPM). (Source: Drug Development Technology)
Source: Drug Development Technology - July 3, 2016 Category: Pharmaceuticals Source Type: news
Class 4 Drug Alert (caution in use): Pemetrexed 25mg/ml concentrate for solution
for infusion
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a class 4 drug alert for Peme (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - June 16, 2016 Category: Drugs & Pharmacology Source Type: news
